We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cingulate Inc (CING) USD0.0001

Sell:$4.75 Buy:$4.79 Change: $0.0719 (1.48%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.75
Buy:$4.79
Change: $0.0719 (1.48%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.75
Buy:$4.79
Change: $0.0719 (1.48%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Contact details

Address:
1901 W. 47Th Place
KANSAS CITY
66205
United States
Telephone:
+1 (913) 9422300
Website:
https://www.cingulate.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CING
ISIN:
US17248W3034
Market cap:
$15.61 million
Shares in issue:
3.21 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Shane Schaffer
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Raul Silva
    Co-Founder, Executive Vice President, Chief Science Officer
  • Matthew Brams
    Co-Founder, Executive Vice President, Chief Medical Officer
  • Jennifer Callahan
    Chief Financial Officer, Senior Vice President, Principal Accounting Officer
  • Laurie Myers
    Chief Operating Officer, Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.